anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Osteoarthritis (OA) is a degenerative joint disease, Increasingly, mitochondrial autophagy has been found to play an important regulatory role in the prevention and treatment of osteoarthritis. Koumine is a bioactive alkaloid extracted from the plant Gelsemium elegans. In previous research, Koumine was found to have potential in improving the progression of OA in rats. However, the specific mechanism of its action has not been fully explained. Therefore, the aim of this study was to investigate whether Koumine can alleviate OA in rats by influencing mitochondrial autophagy. In the in vitro study, rat chondrocytes (RCCS-1) were induced with IL-1β (10 ng/mL) to induce inflammation, and Koumine (50 μg/mL) was co-treated. In the in vivo study, a rat OA model was established by intra-articular injection of 2% papain, and Koumine was administered orally (1 mg/kg, once daily for two weeks). It was found that Koumine effectively reduced cartilage erosion in rats with osteoarthritis. Additionally, it decreased the levels of inflammatory factors such as IL-1β, IL-6, and extracellular matrix (ECM) components MMP13 and ADAMTS5 in chondrocytes and articular cartilage tissue, while increasing the level of Collagen II.Koumine inhibited the production of reactive oxygen species (ROS) in cartilage tissue and increased the number of autophagosomes in chondrocytes and articular cartilage tissue. Additionally, it upregulated the expression of mitochondrial autophagy proteins LC3Ⅱ/Ⅰ, PINK1, Parkin, and Drp1. The administration of Mdivi-1 (50 μM) reversed the enhanced effect of Koumine on mitochondrial autophagy, as well as its anti-inflammatory and anti-ECM degradation effects in rats with OA. These findings suggest that Koumine can alleviate chondrocyte inflammation and improve the progression of OA in rats by activating PINK1/Parkin-mediated mitochondrial autophagy.
Articular cartilage defects have a weak potential for self-repair because of the reduced mitotic capacity of chondrocytes in vivo. Because some patients with articular cartilage defects may progress to osteoarthritis, such defects need to be repaired even though their exact natural course remains obscure. Traditional methods for repair, such as micro fracture, perforations, abrasion arthroplasty, have not produced consistent satisfactory long term clinical results. Transplantation of autologous bone marrow MSCs expanded in culture would be a promising approach in the repair of articular cartilage defects in human osteoarthritic knees. This method is clinically straightforward to perform because autologous cells can be readily harvested and expanded in culture without losing their capacity to differentiate into chondrocytes. The purpose of this study was to evaluate the clinical results obtained with autologous MSCs expanded in culture for the treatment of full-thickness chondral defects in human knee.
PURPOSE: A pharmaceutical composition containing a compound is provided to suppress cancer cell proliferation and to induce cancer cell apoptosis. CONSTITUTION: A pharmaceutical composition for preventing or treating cancer contains a compound of chemical formula 1 or 2, pharmaceutically acceptable salt thereof, or a derivative thereof as an active ingredient. The composition additionally contains pharmaceutically acceptable carrier, excipient, or diluents. The composition also contains an angiogenesis inhibitor. A health functional food for preventing or treating cancer contains the compound, salt, or derivative. The health functional food additionally contains sitologically acceptable food additive.
Participating caregivers will turn in receipts from grocery store purchases. At each of three study visits, participants in the reimbursement arm will receive reimbursement of up to 10% of their usual SNAP benefits for specific whole grain foods purchased at one of two chain stores in the previous month.
It is intended to provide a substituted cycloalkene derivative represented by the general formula (I) which has an action of suppressing intracellular signal transduction or cell activation caused by endotoxin and a cell response such as hyperproduction of an inflammatory mediator caused by them, a pharmacologically acceptable salt thereof, a method for producing the same, and a pharmaceutical containing the cycloalkene derivative as an active ingredient, which is excellent in prevention and/or treatment of a disease such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure or the like). General formula (I): {In the formula, X and Y represent a group which forms the ring A with the carbon atom of the ring B to which X and Y are bound or the like. l and m independently represent an integer of 0 to 3 and l+m is 1 to 3. R<sup>1</sup> represents an aliphatic hydrocarbon group which may be substituted or the like. n represents an integer of 0 to 3. R<sup>2</sup> represents a hydrogen atom, an alkyl group which may be substituted or the like, R<sup>3</sup> represents a phenyl group which may be substituted or the like, and R<sup>5</sup> represents a hydrogen atom, an alkyl group which may be substituted or the like.}.
Echocardiography enables the intensivist to assess the patient with circulatory failure. It allows the clinician to identify rapidly the type and the cause of shock in order to develop an effective management strategy. Important characteristics in the setting of shock are that it is non-invasive and can be rapidly applied. Early and repeated echocardiography is a valuable tool for the management of shock in the intensive care unit. Competency in basic critical care echocardiography is now regarded as a mandatory part of critical care training with clear guidelines available. The majority of pathologies found in shocked patients are readily identified using basic level 2D and M-mode echocardiography. The four core types of shock (cardiogenic, hypovolemic, obstructive, and septic) can readily be identified by echocardiography. Echocardiography can differentiate the different pathologies that may be the cause of each type of shock. More importantly, as a result of more complex and elderly patients, the shock may be multifactorial, such as a combination of cardiogenic and septic shock, which emphasises on the added value of transthoracic echocardiography (TTE) in such population of patients. In this review we aimed to provide to clinicians a bedside strategy of the use of TTE parameters to manage patients with shock. In the first part of this overview, we detailed the different TTE parameters and how to use them to identify the type of shock. And in the second part, we focused on the use of these parameters to evaluate the effect of treatments, in different types of shock.
Study participants will be asked to attend the clinic on two separate occasions. Each session will last less than one hour. Patients will be asked to complete validated psychometric surveys assessing 1) their level of claustrophobia, 2) their level of anxiety and 3) their (baseline) motion sickness, before and after each session. They will then be rotated 3-4 times on the Nano-X patient rotation system, at varying speeds ranging from 6°/sec to 45°/sec. Each rotation will be designed to simulate a typical radiotherapy treatment; that is 9 angles, pausing for around 30 seconds at each angle. Straight after each rotation, patients will again complete the questionnaire assessing their anxiety levels and motion sickness.
Periodontitis is the inflammation of the tissues supporting the teeth which include cementum, gingiva, periodontal ligaments and alveolar bone. Periodontitis typically follows untreated gingivitis, a shift in the composition of biofilm from gram positive cocci to dominantly gram negative actinomyces and infection by proteolytic obligate anaerobes resulting in progressive destruction of periodontal ligament, formation of pocket around the teeth and resorption of alveolar bone with ultimately loosening or loss of teeth. The present project will be associated with very common forms of periodontitis (in which the inflammation results in periodontal tissue destruction and alveolar bone resorption) and gingivitis (in which the inflammation is confined to gingivae and is reversible with good oral hygiene). Lemongrass (Cymbopogon Citratus) oil mouthwash can be used with subgingival scaling to eliminate the pathogens of periodontitis and to treat the inflammation and the damage done to periodontium by it. It possess anti-oxidant, anti-inflammatory, anti-microbial, anti-fungal and astringent properties. Citral epoxide which is an ingredient of lemongrass extract is an active anti-inflammatory and anti-bacterial agent. It is useful in dentistry and has a wide role in the treatment of periodontal diseases. Transforming growth factor beta (TGF-β) is a multifunctional cytokine belonging to transforming growth factor superfamily and its elevated levels are detectable in inflammatory and healing process The present project will be conducted to evaluate the expression of TGF-β levels in chronic periodontitis patients after ultrasonic scaling and using 0.25% lemongrass oil mouthwash. TGF-β is a salivary marker of periodontitis. A sample size of 30 patients either male or female aged between 40 and 60 years with chronic localized or generalized periodontitis with pocket depth of \>3mm affecting at least two nonadjacent sites/teeth will be selected. This sample will be divided into two equal groups. In the experimental 1 group, only sub-gingival scaling will be performed. In the experimental 2 group, sub-gingival scaling will be performed, followed by use of 0.25% lemongrass oil mouthwash twice daily for 14 days. Saliva sample will be collected on days 0, 7 and 14 and level of salivary biomarker, TGF-β will be measured with the ELISA technique. The data will be entered and analyzed using SPSS 22. Mean ±SD will be given for quantitative variables like TGF-β level. A p value of ≤ 0.05 will be considered as statistically significant.
OBT076 administered intravenously (IV) every 3 weeks in escalating dose cohorts during Part A and OBT076 administered at or below the MTD in the Part B expansion cohort. In Part C sequential administration of OBT076 administered at the recommended phase 2 dose (RP2D) followed by Balstilmab. Part D will evaluate the safety, tolerability, preliminary efficacy of OBT-076 in combination with Balstilmab.
The invention belongs to the field of medicines, and particularly relates to a medicine for improving blood brain barrier permeability and application thereof. The active ingredient of the medicine for improving the blood brain barrier permeability is nitazoxanide or tizoxanide. The administration route of the medicament for improving the blood brain barrier permeability is injection administration or external administration. The external preparation is preferably an external gel preparation. The medicinal adjuvants of the external gel preparation comprise carbomer 941, propylene glycol, glycerol, triethanolamine, ethanol and purified water. The medicine for improving the blood brain barrier permeability can play an opening role in a normal blood brain barrier so that other medicines can conveniently pass through the blood brain barrier, thereby playing a drug effect on a central nervous system, and the medicine for improving the blood brain barrier permeability has a certain inhibition effect on blood brain barrier damage when pathological blood brain barrier damage occurs.
Targeted muscle reinnervation (TMR) is a relatively recent surgical innovation that involves the coaptation of major peripheral nerves to a recipient motor branch that innervates an expendable muscle target. The original indication for TMR was augmentation and optimization of myoelectric signals in the amputated limb for use of myoelectric prosthetics. Incidentally, surgeons and patients discovered that the technique also could treat and prevent phantom and residual limb pain. TMR is performed at the time of amputation or delayed any time after the amputation, and TMR can also be performed at any level of amputation. In the upper extremity, studies have detailed the various techniques and coaptations possible at each amputation level to create intuitive myoelectric signals and treat neurogenic pain. Treatment of peripheral nerves in the amputee with TMR should be a consideration for all patients with major upper extremity amputations, especially at large institutions able to support multidisciplinary limb salvage teams. This review article summarizes the current literature and authors' techniques and recommendations surrounding TMR in the upper extremity amputee including techniques relevant to each level of upper extremity amputation.
Neonates exposed to venlafaxine hydrochloride extended-release capsules, other SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), or SSRIs (Selective Serotonin Reuptake Inhibitors), late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome (see ). When treating a pregnant woman with venlafaxine hydrochloride extended-release capsules during the third trimester, the physician should carefully consider the potential risks and benefits of treatment (see ). , PRECAUTIONSDrug Interactions-, CNS-Active DrugsDOSAGE AND ADMINISTRATION
A dentifrice composition contains as the sole or principal cleansing and polishing ingredient from 5% to 50% by weight of the dentifrice of particulate dehydrated silica gel having an average particle diameter from 2 to 20 microns and a surface area of at least 600 square metres per gram. The composition may also contain a silica thickening agent, e.g. pyrogenic silica or silica aerogel of average particle diameter below 4 microns and a surface area of less than 400 square metres per gram. Up to 10% by weight of the dentifrice of conventional dental abrasives, e.g. waterinsoluble sodium metaphosphate, can be included in the compositions. The dentifrice may also contain a soap or synthetic detergent (as foaming agent), flavouring materials, buffers, sweeteners (such as saccharin), humectants, preservatives, colouring materials, opacifying agents (e.g. TiO 2 ), powdered polymers (such as an alpha-olefin polymer, e.g. polyethylene), carriers and softeners (e.g. glycerine, sorbitol, propylene glycol or polyethylene glycol) and binders (e.g. gum tragacanth, sodium carboxymethylcellulose, hydroxyethylcellulose, carrogheen and its derivatives, starch derivatives and locust bean gum). The composition may contain prophylactic or therapeutic agents such as germicides e.g. hexachlorophene, the sarcosinates antibiotics e.g. tyrothrycin, chlorophyllins astringent salts and watersoluble ionizable fluorine-containing compounds e.g. sodium fluoride, stannous fluoride and sodium monofluorophosphate.
UNLABELLED: Although suppressed cAMP levels have been linked to cancer for nearly five decades, the molecular basis remains uncertain. Here, we identify endosomal pH as a novel regulator of cytosolic cAMP homeostasis and a promoter of transformed phenotypic traits in colorectal cancer. Combining experiments and computational analysis, we show that the Na+/H+ exchanger NHE9 contributes to proton leak and causes luminal alkalinization, which induces resting [Ca2+], and in consequence, represses cAMP levels, creating a feedback loop that echoes nutrient deprivation or hypoxia. Higher NHE9 expression in cancer epithelia is associated with a hybrid epithelial-mesenchymal (E/M) state, poor prognosis, tumor budding, and invasive growth in vitro and in vivo. These findings point to NHE9-mediated cAMP suppression as a pseudostarvation-induced invasion state and potential therapeutic vulnerability in colorectal cancer. Our observations lay the groundwork for future research into the complexities of endosome-driven metabolic reprogramming and phenotype switching and the biology of cancer progression.
IMPLICATIONS: Endosomal pH regulator NHE9 actively controls cytosolic Ca2+ levels to downregulate the adenylate cyclase-cAMP system, enabling colorectal cancer cells to acquire hybrid E/M characteristics and promoting metastatic progression.
The present invention relates to the field of immunotherapy, in particular adoptive T cell therapy, T Cell Receptor (TCR) gene therapy and vaccination. The invention provides a method of preparing nucleic acids encoding a TCR alpha chain construct (TRA) and a TCR beta chain construct (TRB) of a TCR construct specific for an epitope from an antigen presented on the Major Histocompatibility Complex (MHC), the method comprising contacting T cells isolated from a donor with a library of artificial Antigen Presenting Cells (APCs) comprising cells expressing all MHC I or MHC II alleles present in the donor, preferably in K562 cells. The TCR constructs may be expressed in T cells, which are useful for adoptive T cell therapy of, for example, cancer, viral infection, or autoimmune disease. The invention also provides a method of identifying an epitope recognized by the TCR. The immunogenic epitopes recognized by the TCRs can be used to develop vaccine formulations that induce antigen-specific T cell immunity in patients. The invention also provides pairs of two TCR constructs and respective immunogenic epitopes obtained by the methods of the invention, wherein the epitopes are from Human Papillomavirus (HPV) 16 (also known as alphapapillomavirus 9) oncoprotein E5 and human Cytomegalovirus (CMV) protein pp 65.
Dermatological compositions comprising a multiplicity of particles are described, at least one of the particles comprising porous and/or polycrystalline silicon. The dermatological compositions those formulated for sun protection applications. The use of porous silicon, polycrystalline silicon, and porous silicon oxide mirrors in the compositions is disclosed. The figure shows a dermatological composition comprising a multiplicity of particles in contact with human skin; a number of particulate mirrors (11) that are in contact with the skin (12). Each particulate mirror (11) comprises a plurality of layers of porous silicon. Radiation (13), such as UV-A radiation, is reflected by the mirrors (11) before the radiation (13) reaches the skin (12). The particulate mirrors (11) form part of a dermatological composition, which also comprises a dermatologically acceptable carrier (14).
The present invention relates to a killed lactobacillus having an immunity regulating function and a method for producing the same. In particular, effects have been exhibited by regulating the activity of a biomarker related to immunity regulation by means of killed bacteria of Lactobacillus brevis NS1401 (donated by Korean Federation of Culture Collections affiliated with Korean Culture Center of Microorganisms, donation number: KCCM11594P, donation date: 30.10.2014) separated from kimchi. Specifically, Lactobacillus brevis NS1401 developed according to the present invention has an excellent immunity regulating effect thereof compared to other strains separated from kimchi, and has high acid resistance and bile acid resistance, so the Lactobacillus brevis NS1401 may also be excellently used as probiotics. The present invention relates to the strain properties of Lactobacillus brevis NS1401 separated from kimchi, an excellent immunity regulating effect thereof when being killed, and a method for producing the same so as to improve effects thereof. Moreover, killed bacteria developed according to the present invention may be variously used in producing a chemical composition, a drinkable intestinal agent, a probiotic composition, a feed additive, and other fermentation products. The method comprises the steps of: sorting a strain having excellent acid resistance and bile acid resistance from kimchi, and heating and killing the strain; and analyzing the strain properties of sorted Lactobacillus brevis NS1401, and improving an immune regulating effect of killed bacteria thereof.
BACKGROUND: Downregulated expression of cold-inducible RNA binding protein (CIRP), a stress-response protein, has been demonstrated in the hearts of patients with heart failure (HF). However, whether CIRP plays a critical role in the pathogenesis of HF remains unknown. Zr17-2 is a recently identified CIRP agonist, which can enhance the expression of CIRP in hearts. Herein, we evaluated the effects of zr17-2 on the development of HF in a rat model of myocardial infarction (MI).
METHODS: Male SD rats were pretreated with CIRP agonist zr17-2 or vehicle saline for 6 consecutive days, followed by MI induction. 1-week post-MI, cardiac function, and structural and molecular changes were determined by echocardiography and molecular biology methods.
RESULTS: Excitingly, we found that pretreatment with zr17-2 significantly attenuated MI-induced cardiac dysfunction and dilation, coupled with reduced infarction size and cardiac remodeling. In addition, increased inflammatory response in the peri-infarcted heart including macrophage infiltration and the expression of inflammatory genes were all significantly decreased by zr17-2 pretreatment, suggesting an anti-inflammatory effect of zr17-2. Moreover, zr17-2 pretreatment also upregulated the antioxidant genes (e.g. NQO-1, Nrf2, and HO-1) level in the hearts. In isolated cultured cardiomyocytes, pretreatment with zr17-2 markedly attenuated cell injury and apoptosis induced by oxidative injury, along with elevation of Nrf2-related antioxidant genes and CIRP. However, silencing CIRP abolished zr17-2's antioxidant effects against oxidative injury, confirming that zr17-2's role is dependent on CIRP.
CONCLUSION: Collectively, our study suggests CIRP plays a crucial role in the development of HF and a beneficial effect of CIRP agonist in preventing MI-induced HF, possibly via anti-inflammatory and anti-oxidant pathways.
This group comprises of patients with ureter stones stones who undergo ureteroscopy procedure. They will be randomized to intra muscular injection Diclofenac Sodium 50 mg. They will also be discharged on oral Tablet Diclofenac Sodium 50 mg for postoperative pain after the ureteroscopy procedure with stent placement.
The method involves providing a consumption unit (1) e.g. catheter, with a type-specific detection-code for usage in a medical device, and storing the detection code in combination with user-identification and determination of a user condition. Data for selection of a design of a supplementary module (30) i.e. casing, for the medical device are provided based on the user condition. A request for supplying the supplementary module is generated based on the selection of the user, where the casing partially surrounds the medical device. Independent claims are also included for the following: (1) a medical home-monitoring system for analysis and therapy of a diabetic patient (2) a computer or network with a program for selection of designs for supplementary module for a medical device (3) a database for processing of data for selection of designs for supplementary module for a medical device.